Presented by: University of Kentucky Department of Pathology

“ Building Strong Bonds: Clinical Chemistry as a Partner in Diagnostic Stewardship and Quality Improvement Initiatives”

      Robert D. Maynard, PhD, DABCC, NRCC

Assistant Professor of Clinical Pathology

Director of Special Chemistry, Point of Care Testing & Blood Gases

Department of Pathology & Laboratory Medicine

University of Kentucky Medical Center

Thursday, March 12, 2026

12:00 – 1:00pm

In-Person MS 147 or Zoom: 

 https://us06web.zoom.us/j/87832764787?pwd=Rgj3iqV6y29XzBe783LTI1Y8Nvwt5g.1

Please sign-in with first, last name and credentials

At the completion of this lecture attendees should be able to:
1. Articulate the critical role of partnership and dialogue between the clinical laboratory and health care providers in advancing quality improvement initiatives.
2. Evaluate the key considerations involved in assessing and implementing new clinical laboratory test methods or technologies aimed at improving diagnostic quality and patient outcomes.
3. Analyze existing ordering practices and develop strategies to implement evidence-based testing algorithms to support diagnostic stewardship in the clinical laboratory.

Disclosure of Financial Interest Summary to Learners
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation